1. Home
  2. LWLG vs IRWD Comparison

LWLG vs IRWD Comparison

Compare LWLG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightwave Logic Inc.

LWLG

Lightwave Logic Inc.

HOLD

Current Price

$8.15

Market Cap

578.6M

Sector

Industrials

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.42

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LWLG
IRWD
Founded
1991
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.6M
526.7M
IPO Year
2011
2009

Fundamental Metrics

Financial Performance
Metric
LWLG
IRWD
Price
$8.15
$3.42
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$4.94
AVG Volume (30 Days)
6.1M
2.3M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
15.79
1400.00
EPS
N/A
0.15
Revenue
$236,855.00
$298,276,000.00
Revenue This Year
N/A
$57.95
Revenue Next Year
N/A
$4.39
P/E Ratio
N/A
$23.53
Revenue Growth
147.74
8.88
52 Week Low
$0.83
$0.55
52 Week High
$9.03
$5.78

Technical Indicators

Market Signals
Indicator
LWLG
IRWD
Relative Strength Index (RSI) 63.42 47.75
Support Level $3.46 $3.07
Resistance Level $8.42 $3.53
Average True Range (ATR) 0.91 0.22
MACD -0.02 0.07
Stochastic Oscillator 70.88 43.72

Price Performance

Historical Comparison
LWLG
IRWD

About LWLG Lightwave Logic Inc.

Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: